NCT02051387View on ClinicalTrials.gov

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Schizophrenia
Interventions
DRUG

Cannabidiol CR

DRUG

Cannabidiol

DRUG

Amisulpride

DRUG

Olanzapine

DRUG

Quetiapine

DRUG

Risperidone

DRUG

Placebo

Trial Locations (2)

50931

Dept. of Pharmacology, University of Cologne, Cologne

68159

Central Institute of Mental Health, Mannheim

All Listed Sponsors
collaborator

University of Cologne

OTHER

lead

Central Institute of Mental Health, Mannheim

OTHER

NCT02051387 - Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study | Biotech Hunter | Biotech Hunter